Association of the Genetic Polymorphism of the CYP19 Intron 4 [TTTA] n Repeat with Familial Prostate Cancer Risk in a Japanese Population

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 4941-4946

  Suzuki, Kazuhiro ^a   Nakazato, Haruki ^a   Matsui, Hiroshi ^a   Koike, Hidekazu ^a   Okugi, Hironobu ^a   Ohtake, Nobuaki ^a   Takei, Tomoyuki ^a   Nakata, Seiji ^a   Hasumi, Masaru ^a   Yamanaka, Hidetoshi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

TTTA n repeat; CYP19; Familial prostate cancer; Genetic polymorphism

Indexed keywords

AROMATASE; CYTOCHROME P450; ESTROGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; CYP19 GENE; ESTROGEN SYNTHESIS; FAMILIAL CANCER; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; INTRON; JAPAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE REPEAT; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SHORT REPEAT ALLELE; TETRANUCLEOTIDE REPEAT;

AGED; AGED, 80 AND OVER; ALLELES; AROMATASE; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRONS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 10744220316     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bratt O: Hereditary prostate cancer. BJU Int 85: 588-598, 2000.
2. Bratt O: Hereditary prostate cancer: clinical aspects. J Urol 168: 906-913, 2002.
3. Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, Brownstein MJ, Bova G.S, Guo H, Bujnovszky P, Nusskern DR, Damberg J-E, Bergh A, Emanuelsson M, Kallioniemi O-P, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM and Isaacs WB: A genome wide search reveals a major susceptibility locus for prostate cancer on chromosome 1. Science (Washington DC) 274: 1371-1374, 1996.
4. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wöhr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanche H, Bellane-Chantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chumakov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P, Cohen D and Cussenot O: Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 62: 1416-1424, 1998.
5. Xu J, Mayers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi O-P, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Grönberg H, Emanuelsson M, Damber J-E, Bergh A, Jonsson B-A, Smith J, Bailey-Wilson J, Caprpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M and Trent J: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 20: 175-179, 1998.
6. Gibbs M, Stanford JL, McIndoe TA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L and Ostrander EA: Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 64: 776-787, 1999.
7. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, Thibodeau SN and Schaid DJ: Evidence for prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 67: 82-91, 2000.
8. Tavtigian SV, Simard J, Teng DHF, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid J, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J Thomas A, Tranchant M, Woodland A-M, Labrie F, Skolnick MH, Neuhausen S, Rommens J and Cannon-Albright LA: A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 27: 172-180, 2001.
9. Carpten J, Nupponen N, Isaacs S, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein D, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi O-P, Burk R, Meyers D, Grönberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W and Trent J: Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30: 181-184, 2002.
10. Suzuki K, Ohtake N, Nakata S, Takei T, Matsui H, Ono Y, Nakazato H, Hasumi M, Koike H, Ito K, Fukabori Y, Kurokawa K and Yamanaka H: Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population. Anticancer Res 22: 3507-3512, 2002.
11. Nakazato H, Suzuki K, Matsui H, Ohtake N, Nakata S and Yamanaka H: Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer, in press.
12. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Koike H, Nakazato H, Okugi H, Hasumi M, Fukabori Y, Kurokawa K and Yamanaka H: Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urol 10: 261-266, 2003.
13. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, Okugi H, Koike H, Ono Y, Ito K, Kurokawa K and Yamanaka H: A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci, in press.
14. Suzuki K, Matsui H, Nakazato H, Koike H, Okugi H, Hasumi M, Ohtake N, Nakata S, Takei T, Hatori M, Ito K and Yamanaka H: Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study. Cancer Lett, in press.
15. Nakazato H, Suzuki K, Matsui H, Koike H, Okugi H, Ohtake N, Takei T, Nakata S, Hasumi M and Yamanaka H: Association of genetic polymorphisms of glutathione- s-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population. Anticancer Res 23: 2897-2902, 2003.
16. Suzuki K, Takezawa Y, Suzuki T, Honma S and Yamanaka H: Synergistic effects of estrogen with androgen on the prostate-effects of estrogen on the prostate of androgen-administered rats and 5-alpha-reductase activity. Prostate 25: 169-176, 1994.
17. Suzuki K, Ito K, Suzuki T, Honma S and Yamanaka H: Synergistic effects of estrogen and androgen on the prostate: effects of estrogen on androgen- and estrogen-receptors, BrdU uptake, immunohistochemical study of AR, and responses to antiandrogens. Prostate 26: 151-163, 1995.
18. Leav I, Ho SM, Ofner P, Merk FB, Kwan PW and Damassa D: Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J Natl Cancer Inst 80: 1045-1053, 1998.
19. Leav I, Galluzzi CM, Ziar J, Stork PJ, Ho SM and Loda M: Mitogen-activated protein kinase and mitogen-activated phosphatase-1 expression in the Noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab Invest 75: 361-370, 1996.
20. Vermeulen A, Kaufman JM, Goemaere S and van Pottelberg I: Estradiol in elderly men. Aging Male 5: 98-102, 2002.
21. Hiramatsu M, Maeara I, Ozaki M, Harada N, Orikasa S and Sasano H: Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 31: 118-124, 1997.
22. Castagnetta LA, Granata OM, Bellavia V, Amodio R, Scaccianoce E, Notarbartolo M, Follari MR, Miceli MD and Carruba G: Product of aromatase activity in intact LNCaP and MCF-7 human cancer cells. J Steroid Biochem Mol Biol 61: 287-292, 1997.
23. Thompson PA and Ambrosone C: Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr 27: 125-134, 2000.
24. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P and Borresen-Dale AL: A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 8: 43-48, 1998.
25. Siegelmann-Danieli N and Buetow KH: Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 79: 456-463, 1999.
26. Healey CS, Dunning AM, Durocher F, Teare D, Pharoah PD, Luben RN, Easton DF and Ponder BA: Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 21: 189-193, 2000.
27. Haiman CA, Hankinson SE, Speigelman DM, De Vivo I, Colditz GA, Willett WC, Speizer FE and Hunter DJ: A tetranucleotide repeat polymorphism in CYP19 and breast cancer. Int J Cancer 87: 204-210, 2000.
28. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL and Cussenot O: Prostate carcinoma risk and allelic variants of gene involved in androgen biosynthesis and metabolism pathways. Cancer 92: 1130-1137, 2001.
29. Azzouzi R, Cochand-Priollet B, Mangin P, Fournier G, Berthon P, Latil A and Cussenot O: Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate. Eur J Endocrinol 147: 479-484, 2002.
30. Berstein LM, Imyanitov EN, Suspitsin EN, Grigoriev MY, Sokolov EP, Togo A, Hanson KP, Poroshina TE, Vasiljev DA, Kovalevskij AY and Gamajunova VB: CYP19 gene polymorphism in endometrial cancer patients. J Cancer Res Clin Oncol 127: 135-138, 2001.
31. Yoshida KI, Yano M, Chiba K, Honda M and Kitahara S: CAG repeat length in the androgen receptor gene is enhanced in patients with idiopathic azoospermia. Urology 54: 1078-81, 1999.
32. Suspitsin EN, Grigoriev MY, Togo AV, Kuligina ES, Belogubova EV, Pozharisski KM, Chagunava OL, Sokolov EP, Theillet C, Berstein LM, Hanson KP and Imyanitov EN: Distinct prevalence of the CYP19 Δ3(TTTA)7 allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. Eur J Cancer 38: 1911-1916, 2002.
33. Miyoshi Y, Iwao K, Ikeda N, Egawa C and Noguchi S: Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer 89: 325-328, 2000.
34. Krontiris TG, Devlin B, Karp DD, Robert NJ and Risch N: An association between the risk of cancer and mutation in the HRAS1 minisatellite locus. N Engl J Med 329: 517-523, 1993.